Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
基本信息
- 批准号:8299488
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-11 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAnimal ModelAnimalsBMP2 geneBlood CirculationBone MarrowBone MatrixBone Morphogenetic ProteinsBone TransplantationCalvariaCholesterol HomeostasisCollagenDefectDevelopmentEffectivenessEmbryoErinaceidaeFamilyFibroblastsFractureFutureGene TargetingGoalsHealedHumanIn VitroInvestigationLigandsLiverMediatingMediator of activation proteinMesenchymalMesenchymal Stem CellsModelingMolecularMolecular Mechanisms of ActionMusNeonatalNuclearOrgan Culture TechniquesOsteogenesisParentsPathway interactionsPlayPropertyProteinsRat-1RattusReceptor ActivationReceptor SignalingRecombinantsRelative (related person)ReportingRoleSignal PathwaySignal TransductionSpeedSpinal FusionStromal CellsStructure-Activity RelationshipTestingTissuesanalogbonebone cellbone healingclinically relevantcomparative efficacycosthealingimmunogenicimprovedin vitro activityin vivoin vivo Modellipid biosynthesisnotch proteinnovelosteogenicosteoprogenitor cellreceptorresponsescaffoldsmall moleculesmoothened signaling pathwaytranscription factor
项目摘要
DESCRIPTION (provided by applicant): We have previously reported that specific endogenously produced small molecule oxysterols, formed in vivo as intermediaries of cholesterol metabolism, have potent osteogenic effects on multipotent mesenchymal stem cells (MSC) in vitro. We have shown that these effects are mediated through activation of the Hedgehog (Hh) signaling pathway, independent of Hh proteins. In addition, we have demonstrated that these oxysterols induce bone formation in neonatal mouse calvaria organ cultures, and bone healing in both a rat calvarial critical-sized defect model and a rat spinal fusion model in vivo. Thus, these oxysterols could potentially replace currently used expensive recombinant bone morphogenetic proteins (BMPs) and autogenous bone grafts for stimulation of local bone formation in non-healing fractures and critical bone defects. In addition, we have shown that when used in combination with BMPs, osteogenic oxysterols greatly reduce the concentration of BMPs required to induce effective osteogenesis in vitro. Accordingly, we have recently performed oxysterol structure activity relationship (SAR) studies that have resulted in the synthesis of a novel family of potent oxysterol analogues that possess osteogenic and anti-adipogenic activity equal or superior to the parent oxysterols. However, in addition to activating the Hh pathway, osteogenic oxysterols also activate liver X receptor (LXR) signaling whose role in osteogenesis is unclear and may promote oxysterol-induced osteogenesis by regulating targets of Notch signaling. Therefore, we hypothesize that osteogenic oxysterol analogues activate Hh and LXR signaling in osteoprogenitor cells and that both signaling pathways play an important role in osteogenic responses to oxysterols. To examine this hypothesis, we will pursue the following specific aims: 1) Elucidate the molecular signaling profile of osteogenic oxysterol analogues to determine the role and relative activation levels of Hh and LXR signaling in oxysterol-induced osteogenesis in vitro; 2) Examine the osteogenic activity of oxysterols and their mechanism of action in vivo for local administration using the rat spinal fusion and femoral defect models, while defining the optimal scaffold for local delivery and elucidating the role of Hh signaling in oxysterol effects in vivo; and 3) Examine the role of baseline and oxysterol-induced Hh pathway activity in BMP2-induced osteogenesis by determining whether Hh signaling through Gli transcription factors mediates the synergy between oxysterols and BMPs in stimulating osteogenesis in vitro and in vivo, and whether oxysterols may potentially improve the quality of the newly formed bone by inhibiting BMP2 stimulation of adipogenesis. These studies will provide important new information regarding the basic mechanisms regulating osteogenesis and the effects of oxysterols, as well as guidance for future investigations of oxysterols as a potential new class of osteoinductive agents for localized and perhaps systemic osteoregeneration.
描述(由申请人提供):我们之前已经报道了体内形成的作为胆固醇代谢中间体的特异性内源性产生的小分子氧固醇在体外对多能间充质干细胞(MSC)具有强效成骨作用。我们已经表明,这些影响是通过激活刺猬(Hh)信号通路介导的,独立于Hh蛋白。此外,我们已经证明,这些氧固醇诱导新生小鼠颅骨器官培养物中的骨形成,以及大鼠颅骨临界尺寸缺损模型和大鼠脊柱融合模型中的骨愈合。因此,这些氧固醇可以潜在地替代目前使用的昂贵的重组骨形态发生蛋白(BMP)和自体骨移植物,用于刺激非愈合性骨折和严重骨缺损中的局部骨形成。此外,我们已经表明,当与BMP组合使用时,成骨氧固醇大大降低了体外诱导有效成骨所需的BMP浓度。因此,我们最近进行了氧固醇结构活性关系(SAR)研究,导致合成了一个新的家族的有效的氧固醇类似物,具有成骨和抗脂肪形成活性等于或上级的母体氧固醇。然而,除了激活Hh途径之外,成骨氧固醇还激活肝脏X受体(LXR)信号传导,其在骨生成中的作用尚不清楚,并且可以通过调节Notch信号传导的靶点来促进氧固醇诱导的骨生成。因此,我们假设成骨氧化固醇类似物激活骨祖细胞中的Hh和LXR信号传导,并且这两种信号传导途径在对氧化固醇的成骨反应中起重要作用。为了验证这一假设,我们将进行以下具体的目标:1)阐明成骨氧固醇类似物的分子信号转导谱,以确定Hh和LXR信号转导在氧固醇诱导的体外成骨中的作用和相对活化水平; 2)使用大鼠脊柱融合和股骨缺损模型检查氧固醇的成骨活性及其在局部给药的体内作用机制,同时定义了用于局部递送的最佳支架并阐明了Hh信号传导在体内氧化固醇效应中的作用;和3)通过确定Hh信号通过Gli转录因子是否介导氧固醇和BMP之间在体外和体内刺激骨生成中的协同作用,检查基线和氧固醇诱导的Hh途径活性在BMP 2诱导的骨生成中的作用,以及氧固醇是否可以通过抑制BMP 2对脂肪生成的刺激而潜在地改善新形成的骨的质量。这些研究将提供重要的新信息,有关的基本机制,调节成骨和氧化固醇的影响,以及指导未来的调查氧化固醇作为一个潜在的新类别的骨诱导剂局部和全身性骨再生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FARHAD PARHAMI其他文献
FARHAD PARHAMI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FARHAD PARHAMI', 18)}}的其他基金
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
抗纤维化和抗炎半合成氧甾醇 Oxy210 作为非酒精性脂肪性肝炎候选治疗药物的评价
- 批准号:
10697132 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH
半合成氧甾醇候选药物 Oxy210 对 NASH 小鼠模型动脉粥样硬化的影响
- 批准号:
10474926 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling
氧甾醇候选药物 Oxy210,通过靶向刺猬蛋白和 TGFβ 信号传导抑制肺纤维化
- 批准号:
10545973 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion
用于脊柱融合的成骨氧甾醇 (Oxy133) 的治疗开发
- 批准号:
10478295 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion
用于脊柱融合的成骨氧甾醇 (Oxy133) 的治疗开发
- 批准号:
10256352 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH
氧甾醇候选药物在 NASH 小鼠模型中抑制肝纤维化
- 批准号:
10076454 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8186225 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8727972 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8890648 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8501384 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Discovery Grants Program - Individual